VX11-770-108: A Phase 3, 2-Part, Open-Label Study to Ev

  • Regelmann, Warren E (PI)

Project: Research project

Project Details

Description

VX11-770-108: A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are 2 Through 5 Years of Age and Have a CFTR Gating Mutation
StatusFinished
Effective start/end date11/19/121/1/15

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.